Eagle Pharmaceuticals Inc (EGRX) has released an update to notify the public and investors about a regulation fd disclosure.
Eagle Pharmaceuticals, Inc. announced an update to its bendamustine intellectual property portfolio through a press release on January 18, 2024. This information, provided in a press release attached to their Current Report, is not considered “filed” under the Securities Exchange Act of 1934 nor is it to be incorporated into other SEC filings by the company.
For further insights into EGRX stock, check out TipRanks’ Stock Analysis page.
